Treating ER+ Breast Cancer with CDK4/6 Inhibitors [News in Brief]

Data from the MONARCH2, PALOMA-1, and TREnd trials strongly support using CDK4/6 inhibitors alongside standard endocrine therapy for advanced ER-positive breast cancer. Including these targeted agents not only improves progression-free survival but may reverse acquired resistance to hormone treatment.
Source: Cancer Discovery - Category: Cancer & Oncology Tags: News in Brief Source Type: research